A recent study published on December 19, 2024, in the ExRNA journal highlights research from the Novosibirsk Institute of Chemical Biology and Fundamental Medicine, in collaboration with the E.N.

The company’s lead therapeutic candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic ...